glecaprevir + pibrentasvir + ribavirin

This drug is a combination therapy comprised of three antiviral agents: **glecaprevir** (a hepatitis C virus NS3/4A protease inhibitor), **pibrentasvir** (an NS5A inhibitor), and **ribavirin** (a nucleoside analog with broad-spectrum antiviral activity)[2][5]. The combination targets multiple essential steps in the hepatitis C virus (HCV) life cycle, aiming to enhance sustained virological response (SVR) rates by combining the potent pan-genotypic direct-acting antiviral activities of glecaprevir and pibrentasvir with ribavirin’s additional antiviral effect. Used primarily in experimental regimens for chronic HCV infection, including efforts to shorten treatment duration or improve efficacy in high-risk populations, this combination is being studied in investigator-initiated clinical trials rather than as a commercial fixed-dose product[2][4]. Standard clinical care typically uses glecaprevir/pibrentasvir (marketed as Mavyret) without ribavirin, but the addition of ribavirin in research settings seeks to optimize results in particular subgroups, such as patients with high baseline viral loads or specific HCV genotypes[2].

Other names

GLE/PIB + RBVglecaprevir/pibrentasvir plus ribavirin